The impact of anti-IL5 therapies on patients with severe eosinophilic asthma: a proteomic approach
P. Cameli (Siena, Italy), L. Vantaggiato (Siena , Italy), M. D'Alessandro (Siena , Italy), L. Bergantini (Siena, Italy), E. Shaba (Siena, Italy), A. Carleo (Hannover, Germany), F. Di Giuseppe (Chieti, Italy), S. Angelucci (Chieti, Italy), L. Bini (Siena, Italy), E. Bargagli (Siena, Italy), C. Landi (Siena, Italy)
Source: International Congress 2022 – Clinical and translational studies of asthma and COPD: novel mechanisms
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Cameli (Siena, Italy), L. Vantaggiato (Siena , Italy), M. D'Alessandro (Siena , Italy), L. Bergantini (Siena, Italy), E. Shaba (Siena, Italy), A. Carleo (Hannover, Germany), F. Di Giuseppe (Chieti, Italy), S. Angelucci (Chieti, Italy), L. Bini (Siena, Italy), E. Bargagli (Siena, Italy), C. Landi (Siena, Italy). The impact of anti-IL5 therapies on patients with severe eosinophilic asthma: a proteomic approach. 2256
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|